Sequence overlap between autosomal and sex-linked probes on the Illumina HumanMethylation27 microarray  by Chen, Yi-an et al.
Genomics 97 (2011) 214–222
Contents lists available at ScienceDirect
Genomics
j ourna l homepage: www.e lsev ie r.com/ locate /ygenoSequence overlap between autosomal and sex-linked probes on the Illumina
HumanMethylation27 microarray
Yi-an Chen a,b, Sanaa Choufani a, Jose Carlos Ferreira a,b, Daria Grafodatskaya a,
Darci T. Butcher a, Rosanna Weksberg a,b,⁎
a Program in Genetics and Genome Biology, Hospital for Sick Children Research Institute, Toronto, Ontario, Canada
b Institute of Medical Science, University of Toronto, Toronto, Ontario, CanadaAbbreviations: Illumina 27k, The Illumina Inﬁnium
Chip; SNPs, single-nucleotide polymorphisms; AMD, ab
⁎ Corresponding author. Division of Clinical and Metab
Children, 525 University Avenue, Toronto, Ontario,
4168135345.
E-mail address: rosanna.weksberg@sickkids.ca (R. W
0888-7543/$ – see front matter © 2010 Elsevier Inc. Al
doi:10.1016/j.ygeno.2010.12.004a b s t r a c ta r t i c l e i n f oArticle history:
Received 12 August 2010
Accepted 18 December 2010
Available online 4 January 2011
Keywords:
Illumina Inﬁnium HumanMethylation
27 BeadChip
Non-speciﬁc cross-reactive probe
Sex-speciﬁc DNA methylation
Polymorphic CpG
Single-nucleotide polymorphism
DNA methylationThe Illumina Inﬁnium HumanMethylation27 BeadChip (Illumina 27k) microarray is a high-throughput
platform capable of interrogating the human DNA methylome. In a search for autosomal sex-speciﬁc DNA
methylation using this microarray, we discovered autosomal CpG loci showing signiﬁcant methylation
differences between the sexes. However, we found that the majority of these probes cross-reacted with
sequences from sex chromosomes. Moreover, we determined that 6–10% of the microarray probes are non-
speciﬁc and map to highly homologous genomic sequences. Using probes targeting different CpGs that are
exact duplicates of each other, we investigated the precision of these repeat measurements and concluded
that the overall precision of this microarray is excellent. In addition, we identiﬁed a small number of probes
targeting CpGs that include single-nucleotide polymorphisms. Overall, our ﬁndings address several technical
issues associated with the Illumina 27k microarray that, once considered, will enhance the analysis and
interpretation of data generated from this platform.HumanMethylation27 Bead-
solute methylation difference.
olic Genetics, Hospital for Sick
Canada M5G 2L3. Fax: +1
eksberg).
l rights reserved.© 2010 Elsevier Inc. All rights reserved.1. Introduction
Numerous peer-reviewed papers have been published using the
Illumina Inﬁnium HumanMethylation27 BeadChip (Illumina 27k).
These papers range from basic science initiatives, characterizing
differences in DNA methylation patterns between human embryonic
stem cells and developing human fetal liver to clinical issues,
predicting outcomes for patients with acute myeloid leukemia using
DNA methylation proﬁles [1,2]. However, little has been published
about the design of the microarray probes, which could signiﬁcantly
impact the integrity and interpretation of the data generated.
The Illumina 27k platform is one of the most comprehensive
microarrays for genome-wide DNA methylation analysis [3]. It
interrogates 27,578 CpG sites (CpGs) at single-nucleotide resolution,
covering more than 14,000 RefSeq genes. These CpGs map to the
promoter regions of genes with an average coverage of 2 CpGs per
gene and more extensive coverage (3–20 CpGs) for cancer-related
and imprinted genes [4]. This microarray platform relies on thehybridization between microarray probes (50-mer oligonucleotides)
and sodium bisulﬁte-modiﬁed genomic input DNA. Sodium bisulﬁte
converts unmethylated cytosine to uracil (subsequently to thymine
after PCR) but methylated cytosine is protected and remains a
cytosine. There are two probes for each CpG site, one is speciﬁc for the
methylated CpG and the other is for the unmethylated CpG. The two
probes differ only at the 3′-end nucleotide, which hybridizes to the
target CpG and allows the probes to distinguish between the
methylated and the unmethylated target sequence. Only when the
end nucleotide of the probe hybridizes to the corresponding type of
CpG (methylated or unmethylated) can single-base extension occur
and release the ﬂuorescent signal for detection. The DNA methylation
level for a CpG site is determined by dividing the signal intensity for
the methylated CpG by the sum of both the methylated and
unmethylated CpGs.
In this report, we demonstrate the existence of non-speciﬁc probes
in the Illumina 27k microarray. We describe a subset of non-speciﬁc
probes cross-reacting with non-target sex chromosome sequences
that led to false discovery of autosomal sex-speciﬁc DNA methylation
[5]. Further, we found that non-speciﬁcity is not limited to probes
cross-reacting to sex chromosomes but that 6–10% of probes on this
microarray are non-speciﬁc. In addition, wewere able to demonstrate,
using this group of non-speciﬁc probes that are replicates of each
other, the precision level of this microarray platform. Finally, we
discovered a number of sequence-speciﬁc CpG probes that overlap
single-nucleotide polymorphisms (SNPs). These probes have the
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existence of SNPs in the target CpGs.
2. Results
2.1. Non-speciﬁc probes lead to false discovery of sex-speciﬁc
DNA methylation
The existence of non-speciﬁc cross-reacting probeswas discovered
when we tested a hypothesis asking if there are sex-speciﬁc
differences in DNA methylation of autosomal CpGs in normal
individuals. Using the Illumina platform, we compared the DNA
methylation status of 26,486 autosomal CpGs in the promoters of
13,890 genes in age-matched males (n=12) versus females (n=12).
All genome-wide DNA methylation data were derived from whole
blood lymphocytes of healthy individuals. Quality control and
interarray normalization were performed (see Materials and meth-
ods). A non-parametric signiﬁcance test, Mann–Whitney U, and false
discovery rate (FDR) threshold of 0.05 were used. We identiﬁed 19
autosomal CpGs in 18 genes that showed signiﬁcant sex-speciﬁc DNA
methylation (Table 1; Supplemental Fig. 1). We further investigated
the most signiﬁcant CpG site from our analysis that showed the
highest difference in DNA methylation between males and females.
This CpG mapped to the promoter region of TLE1. Surprisingly, we
found TLE1 to have a pseudogene on the X chromosome [6]. We next
performed a BLAT search of the probe sequences targeting the TLE1
CpG, andwe found the probe to be non-speciﬁc and cross-reactive to a
non-target sequence (100% identical) in the pseudogene of TLE1.
We performed BLAT searches for the remaining signiﬁcant probes
and found 12 of the 19 probes to have non-target cross-reactive
sequences on the sex chromosomes (Supplemental Table 1; see
Materials and methods). The remaining 7 CpGs demonstrated sex-
speciﬁc DNA methylation levels that were not considered technical
artifacts because they only mapped to relatively short sequences
(7–24 bp) on sex chromosomes compared to their unique target
sequences on autosomes (Table 1). To demonstrate that these short
sequences were not cross-reactive, we selected one CpG site
(cg08532057, NUPL1) from this group for further validation. We
chose the NUPL1 CpG out of the 7 non-artifactual candidates, becauseTable 1
Sex-speciﬁc DNA methylation are technical artifacts created by non-speciﬁc probes.
GENE Chr TargetID Male,
AVG_Beta
Female,
AVG_Beta
TLE1 9 cg15915418 9% 48%
GLUD1 10 cg11673803 26% 45%
C6orf68 (NUS1) 6 cg27063525 2% 19%
TDGF1 3 cg10242476 67% 55%
LRRC2 3 cg07514381 83% 71%
FLJ20582 (ZNF770) 15 cg05924191 57% 67%
DPPA3 12 cg08284151 41% 52%
FLJ43276 (UBE2Q2P1) 15 cg13150977 12% 4%
RAB9P1 5 cg10846922 71% 79%
FLJ43276 (UBE2Q2P1) 15 cg18393722 11% 4%
BAG1 9 cg07711515 88% 82%
POU3F1 1 cg21243096 6% 12%
FLJ20444 9 cg01600189 31% 19%
NUPL1 13 cg08532057 14% 25%
DDX43 6 cg08124399 72% 81%
MYF5 12 cg21126707 31% 39%
STYXL1 7 cg17412351 52% 46%
THBS4 5 cg20714328 69% 75%
DECR1 8 cg18485485 3% 5%
The CpGs shown to have sex-speciﬁc DNA methylation by Liu et al. are underlined in the 1s
mean methylation differences; p value indicated the signiﬁcance of the methylation differen
alignment between the cross-reactive target and the target sequence. Number of matching
cross-reactive sequence, and how similar it is compared to the target sequence. All cross-r
because detection signals are released only if the end-nucleotide (i.e., CpG-containing end)
only showed the BLAT result of cross-reactive target that had the largest number of matchithe probe targeting the NUPL1 CpG has the best sex chromosome
sequence match (100% identity, 20 matching bases) and thus has the
highest likelihood to be cross-reactive compared to the other 6 probes
(Table 1). We performed bisulﬁte-pyrosequencing of the CpG
targeted by the microarray probe and an adjacent CpG (see Materials
and methods). The pyrosequencing and microarray results had a
correlation R2 of 0.78 (Supplemental Fig. 2). We again observed the
sex-speciﬁc DNA methylation to be signiﬁcant for NUPL1 CpGs. The
DNA methylation level was 36% (SD: 5%) in females compared to 24%
(SD: 2%) in males (t-test: p=1.82E­06; Fig. 1; Supplemental Fig. 3).
Because the signiﬁcant methylation difference observed for NUPL1 on
the microarray could be conﬁrmed in an independent assay, it was
therefore not considered a technical artifact.
2.2. An estimated 6–10% of the Illumina 27k microarray probes
are non-speciﬁc
To determine the extent of non-speciﬁc probes on the Illumina 27k
microarray, we performed BLAT searches on all the probe sequences
against the same reference genome (NCBI build 36.1, hg18) used by
Illumina for the microarray design (see Materials and methods). The
reference genome was additionally bisulﬁte-converted in silico for
BLAT searches. Of the all 27,578 probes, we found 6–10% to be non-
speciﬁc with potential cross-reactivity that could compromise true
signal detection by the microarray (Table 2). The selection of the
probes with the highest likelihood of representing true cross-reactive
probes was based on four criteria: at least 90% identity, 40–50
matching bases, end-nucleotide match, and gapless in the sequence
alignment (see Materials and methods). The list of non-speciﬁc
probes can be downloaded from http://www.sickkids.ca/Research/
Weksberg-Lab/Publications/index.html. Next, we investigated the
source of this cross-reactivity. The BLAT search was again performed
for the probe sequences of 14 randomly chosen non-speciﬁc probes in
order to locate where the cross-reactivity occurred. We observed two
main reasons for the cross-reactivity. The cross-reactivity occurred
when the target contained repetitive sequences, or when the target
sequences were located at the gene promoters of duplicated genes,
homologous genes, or pseudogenes (Table 3). The probes displaying
the highest rank among cross-reactive probes mapped either toFemale,
Delta Beta
Female,
p value
Sex Chr Match
Span
Match
Identity
# Matching
bases
39% 3.8E­05 X 50 100% 50
19% 3.8E­05 X 50 100% 50
17% 3.8E­05 X 50 100% 50
­12% 4.2E­03 X 50 98% 49
­12% 3.8E­05 X 50 100% 50
11% 6.3E­04 X 50 96% 48
11% 9.7E­04 X 50 96% 48
­9% 9.7E­04 Y 42 98% 41
8% 4.2E­03 X; Y 50; 50 98; 96% 49; 48
­7% 4.1E­04 Y 50 94% 47
­6% 3.3E­02 X 50 100% 50
6% 4.2E­02 X 50 92% 46
­12% 3.0E­03 X 18 100% 18
10% 4.2E­03 X 20 100% 20
9% 3.3E­02 X 12 100% 12
8% 4.2E­02 X 18 100% 18
­6% 2.5E­02 Y 12 100% 12
6% 4.2E­02 X 7 100% 7
2% 4.2E­02 X 24 96% 23
t column [5]. AVG_Beta indicated the mean methylation level; Delta Beta indicated the
ces; Match Span and Match Identity indicated the span and % identity of the sequence
bases=Match Span × Match Identity. The last 4 columns indicate the location of the
eactive sequences have end-nucleotide matches, which is essential for cross-reactivity
of the probe is hybridized allowing single-base-extension to occur. For each probe, we
ng bases. The horizontal line separates technical artifacts from non-technical artifacts.
Sex
Sex
A
B
Fig. 1. Sex-speciﬁc DNA methylation for NUPL1 using both the Illumina microarray and
the bisulﬁte-pyrosequencing. Box plots of the Illumina (plot A) and pyrosequencing
(plot B) data categorized by sex, with asterisks representing outliers. (A) The %
methylation of NUPL1 was determined from 1 CpG site in the Illumina 27k microarray
and (B) 2 CpGs (one of which is the CpG site interrogated by the microarray) in the
bisulﬁte-pyrosequencing. The samples were the same in both experiments (female,
n=12; male, n=12) except for two samples that were not used in the pyrosequencing
data due to lack of good quality PCR amplicon. The sex-speciﬁc DNA methylation
differences were signiﬁcant in both experiments (t-test p value=3.2E-05 for the
Illumina microarray data; p value=1.8E­06 for the pyrosequencing data). The median
%methylation of NUPL1 is 25% in female and 14% inmale (Illumina 27kmicroarray), and
38% in female and 24% in male (pyrosequencing).
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(cg18616655, cg23995778, cg11032157) of highly homologous gene
families, CGB (CGB, CGB1, CGB2, CGB5, CGB7, and CGB8) and SSX (SSX1,
SSX2, SSX2B, SSX3, SSX5, SSX7, SSX8, and SSX9) and TAS2R (TAS2R43,
TAS2R31, TAS2R30, TAS2R19, and TAS2R50). The rest of these 14 probes
(except for one) had cross-reactivity occurring at their target
homologous genes or duplicated genes, or known pseudogenes. The
one exception (cg04568580) may have pseudogenes of its target that
are not yet annotated.
2.3. Overall precision of the Illumina 27k microarray
Given the high sequence similarity observed between the targets
and the cross-reactive sequences, we suspected that some probesmay
have the same probe sequence as a result of targeting different but
highly homologous genes. Of all 27,578 microarray probes, we found19 pairs and 2 triplets of probes (n=44) with the same 50-nucleotide
probe sequences (Supplemental Table 2). Each duplicate and
triplicate probe set represents repeat measurements of the same
CpG site. Thus, the precision of DNA methylation measurements for
these 21 CpGs could be determined. Using a large cohort of samples
(n=277) that passed the stringent quality control criteria, we were
able to determine the overall precision of the Illumina 27kmicroarray.
The correlation R2 of repeat measurements was 0.991 and the slope of
line of best ﬁt is exactly 1.0007, indicating a very high level of
precision for this microarray platform (Fig. 2). In addition, the
precision can also be reﬂected by the absolute methylation difference
(AMD), which is the difference in the DNA methylation levels
determined by each repeat measurement (see Materials and
methods). Of all 6925 repeat measurements, we found only 5% to
have a methylation difference (or an AMD) of greater than 6%
(Table 4). In our sex-speciﬁc methylation analysis, 18 out of the 19
statistically signiﬁcant methylation differences were 6% or greater
(Table 1). Considering that statistically signiﬁcant methylation
differences found in a microarray study are usually greater than 6%,
we therefore concluded that the precision of the Illumina 27k
microarray is excellent for the majority of experimental protocols.
2.4. A small number of microarray probes target polymorphic CpG sites
In addition to the non-speciﬁc cross-reacting probes and replicate
probes, we discovered probes targeting CpGs that included single-
nucleotide polymorphisms (SNPs) in the Illumina 27k microarray
(Table 5). These polymorphic CpGs were found using SNPnexus
(www.snp-nexus.org), which identiﬁed SNPs in the SNP database
(dbSNP ) using the CpG chromosomal location as input (see Materials
and methods) [7]. Although the number of polymorphic CpGs
targeted by the Illumina microarray is relatively small (67 out of
27,578), their methylation levels as determined by the microarray
were largely dictated by SNP genotype. We demonstrated the
profound effect of SNPs on these CpGs using 24 samples for sex-
speciﬁc DNA methylation (Fig. 3). The best example is shown by
highly methylated CpGs, such as cg22022041 and cg26264314, which
have a SNP (G/A) located at the guanine position. The methylation
levels at these two CpG sites are likely to be SNP-dependent, because
they showed a trimodal distribution that could be explained by SNP
genotypes among the subjects (Fig. 3). Of note, not all CpGs had their
methylation levels entirely determined by the SNP genotype. For
example, cg00729708 and cg03833774 had highly variable methyl-
ation levels that could not be explained only by differences in SNP
genotype (Fig. 3). Therefore, assessing the SNP genotype of the sample
is critical in evaluating methylation levels at such loci to determine
associations between polymorphic CpGs and the variable of interest.
3. Discussion
In this paper we demonstrate some important technical features
that are relevant to the interpretation of data derived from the
valuable and widely used DNA methylation microarray, the Illumina
Inﬁnium HumanMethylation27 BeadChip. The detection of non-
speciﬁc cross-reactive probes in our search for sex-speciﬁc DNA
methylation demonstrates the potential problem of generating false
discoveries in analyses using this microarray platform. That is, the
abundance of repetitive sequences and highly homologous gene loci
across the genome create a potential pitfall for the users of any
microarray platform. As we demonstrated here, the scrutiny of probe
sequences for cross-reactivity led us to dismiss a subset of sex-speciﬁc
methylation differences, speciﬁcally those detected by non-speciﬁc
probes (Table 1). For this reason, it is imperative that researchers use a
second independent method to validate results from microarrays to
correct for non-speciﬁc probes in their analysis and interpretation of
the data. We used bisulﬁte-pyrosequencing to validate some sex-
Table 2
Six percent to 10% of the Illumina 27k array probes are non-speciﬁc depending on the identity cut-off value.
Cutoffs (number of matching bases to the
cross-reactive target)
Cutoffs (40, 41, …, 50) used to deﬁned non-speciﬁc probes
40 41 42 43 44 45 46 47 48 49 50
Total number of probes deﬁned as non-speciﬁc 2801 2774 2737 2701 2666 2631 2550 2392 2147 1775 492
Percentage of all probes deﬁned as non-speciﬁc 10.2% 10.1% 9.9% 9.8% 9.7% 9.5% 9.2% 8.7% 7.8% 6.4% 1.8%
Starting from the cut-off of 50, the percentage of all probes deﬁned as non-speciﬁc did not increasemuch after the cut-off of 46, where the non-speciﬁc probes were deﬁned as probes
with cross-reactive target(s) that had at least 46 matching bases to their target sequences. All cross-reactive targets had at least 90% identity, end-nucleotide match, and gapless in
sequence alignment against the target sequences. The sequence alignment always starts on the CpG-containing end and thereby fulﬁlls the requirement of end-nucleotide match.
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microarray output, for example in NUPL1 (Fig. 1).
The NUPL1 gene encodes a component of the nuclear pore
complex, but the exact function of the gene product is unknown [8].
It has been shown to be highly expressed in the testis of fertile men
compared to that of infertile men, suggesting its function is important
for male fertility [9]. The sex-speciﬁc nature of the DNA methylation
proﬁle in this genomic region implicates a sex-speciﬁc role for NUPL1.
Notably, it could be associated with male infertility secondary to
epigenetic deregulation. Interestingly, another aberrant DNA meth-
ylation pattern – MTHFR promoter hypermethylation in testis – has
been recently reported in association with male infertility [10–12].
Aside from NUPL1, our analysis of sex-speciﬁc DNA methylation and
that of Liu and colleagues [5] by the Illumina 27k microarray
suggested that there are few detectable DNA methylation differences
in autosomal genes between the two sexes that survive statistical
tests of signiﬁcance. That does not mean that autosomal sex-speciﬁc
DNA methylation does not exist in the human genome, as it has been
demonstrated in several targeted gene studies [13–16]. Although
some of these genes, CDKN2A, MTHFR, and MGMT, are also
interrogated by the Illumina 27k microarray, we observed no
signiﬁcant sex-speciﬁc DNA methylation [13,14,16]. Discrepancies
between the targeted gene studies and our microarray analysis can be
explained by differences in the CpG sites evaluated in the targeted
versus microarray experiments for this set of genes. Furthermore,
unlike our analysis, some of these studies analyzed individuals with
certain disorders such as cancer [13,16]. The possibility of sex-speciﬁc
DNAmethylation has also been examined using a differentmicroarray
platform [17]. However, these investigators were very cautious about
their ﬁndings noting that even at the most signiﬁcant locus the
magnitude of the DNA methylation difference between the two sexes
was only 4%, far below the smallest difference of 17% that their
microarray platform could reliably estimate [18].Table 3
Source of cross-reactivity identiﬁed from randomly chosen non-speciﬁc probes in the Illum
Probe_ID Target Cross-reactivity
# Source Targ
cg14757296 HYAL1 854 Repetitive sequence Unre
cg18616655 SSX5 11 Homologous gene SSX1
cg23995778 CGB5 5 Homologous gene CGB,
cg11032157 TAS2R50 4 Homologous gene TAS2
cg05449414 ZNF721 3 Homologous gene ZNF7
cg04568580 PRKRIR 3 Possible pseudogene Unid
cg21663722 FAM182A 3 Homologous gene FAM
cg09607232 MAGEA9 1 Duplicated gene MAG
cg08704606 MRC1 1 Homologous gene MRC
cg17288121 DEFB103A 1 Duplicated gene DEFB
cg09551916 CFHR2 1 Homologous gene CFHR
cg19319490 GUSB 1 Known pseudogene LOC4
cg11174654 GLUD2 1 Homologous gene GLUD
cg21621204 HTN1 1 Homologous gene HTN
All statistics in the cross-reactivity column were generated by the original BLAT searches (p
source and targets sub-columns of the cross-reactivity column were derived from visualizin
BLAT searches on the surrounding genomic sequences of CpGs (“top genomic sequence”
(cg18616655, cg21663722) may also have “possible pseudogenes” that are not yet annotatLiu et al. [5] recently reported several autosomal CpGs possessing
sex-speciﬁc DNA methylation. Using the same Illumina microarray
platform and a smaller sample size with different statistical methods,
we identiﬁed the same signiﬁcant CpGs (Table 1). However, we
recognized that the majority of the observed sex-speciﬁc DNA
methylation differences were technical artifacts of non-speciﬁc
cross-reactive probes, which spuriously detected signals from sex
chromosomal CpGs (Supplemental Table 1). The inherent difference
in copy number of sex chromosomes between the two sexes alone
cannot create sex-speciﬁc DNA methylation signals if the same
methylation level is present in both autosomal and sex chromosomal
CpGs. Unlike a SNP microarray, the methylation microarray measures
the proportion of the methylated DNA, not the copy number of
methylated DNA. Thus, the actual methylation level of the sex
chromosome CpGs and their autosomal counterparts must differ in
order to create sex-speciﬁc DNAmethylation signals detected by non-
speciﬁc probes in the Illumina microarray.
Non-speciﬁc probes have been recognized as giving inaccurate
signals in gene expression microarrays [19–22]. In one of these
studies, non-speciﬁc cross-reactive probes with 75–80% sequence
similarity between non-target and target sequences were demon-
strated to give an alteration of the true signal [19]. Cross-hybridization
in the Illumina 27k microarray likely occurs in a similar way as in the
gene expression microarray study, since both microarray platforms
use probes of 50-mer oligonucleotides [19]. However, the Illumina
27k microarray may be better at preventing non-target sequences
from contributing to the overall signal, because hybridization alone in
this microarray platform is not enough to generate a signal. The signal
is only released when the end-nucleotide of the probe is hybridized
permitting the occurrence of single-base extension. That is why we
have included end-nucleotide match as one of the requirements,
among others, to consider if a probe is non-speciﬁc and potentially
cross-reactive (Table 2). The reason why we did not set a clear cut-offina 27k array.
ets # Matching bases % Identity
lated 49–41 98–90%
, SSX2, SSX2B SSX3, SSX7, SSX8, SSX9 49–46 98–92%
CGB1, CGB2, CGB7, CGB8 50–49 100–98%
R43, TAS2R44, TAS2R47, TAS2R48 49–46 98–92%
18, ZNF595, ZNF732 42–40 95–93%
entiﬁed 50–48 100–96%
182B 50–48 100–96%
EA9B 50 100%
1L1 50 100%
103B 50 100%
1 49 98%
41046 45 90%
1 50 100%
3 48 96%
robe sequences against bisulﬁte-converted reference genome). The information in the
g the location of cross-reactivity in the USCS genome browser, in which we performed
of the Illumina annotation) against the unconverted reference genome. Two probes
ed as cross-reactive targets.
y = 1.0007x + 0.0067 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Fig. 2. Correlation of the replicate probes in 277 Illumina microarrays. The correlation plot, reﬂecting the overall precision of the microarray platform, was derived by plotting
methylation level calls of one of the same-target-sequence probes on X axis and the replicate on the Y axis. The correlation R2 of 0.9914 and the slope of the line of best ﬁt of 1.0007
suggests very high precision of this microarray platform.
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to consider a given probe as non-speciﬁc is the inﬂuence of other
factors in the occurrence of the cross-reactivity. Two examples of
these factors are the position of the mismatch(es) and the type of
matching bases (AT or CG). Cross-reactivity is less likely to occur if the
mismatches are closer to the end nucleotide, where the single-base
extension occurs, and if the matching bases are A or T. For C and G,
matching bases stronger hybridizing forces would form. It is also
worth noting that the two colour signal system (green for G/C and red
for A/T) in this microarray platform can overcome some potential
cross-reactivites if single-base extension does not extend to the
appropriate base.
Our detailed examination of a subset of non-speciﬁc probes in the
Illumina 27k microarray showed that cross-reactive probes arise from
overlaps with repetitive sequences, functional gene families, and from
pseudogenes (Table 3). Pseudogene-parental gene pairs and func-
tional gene families have been shown to exhibit differential promoter
DNA methylation proﬁles regardless of the conserved sequence
homology [23]. Similar to what we observed in our analysis, the
highly homologous autosomal and sex chromosome sequences must
have different methylation levels in order to create the sex-speciﬁc
DNA methylation detected by the non-speciﬁc cross-reactive probes.
The observed methylation difference between autosomal sequences
and highly homologous X-linked sequences can be attributed to X-
inactivation, where CpGs in the inactive X could be either hyper- or
hypomethylated [24–26]. Given that DNA methylation of CpGs in theTable 4
Absolute methylation difference (AMD) between repeat measurements of duplicated probe
Total of 6925 repeat measurements
AMD (greater than) 1% 2% 3% 4%
# Repeat Measurements 4494 2825 1723 1017
% Repeat Measurements 65% 41% 25% 15%
AMD is the absolute methylation difference within each set of duplicate and triplicate pro
precision. In other word, the smaller the number of percentage of repeat measurements that
very few (less than 5%) of repeat measurements had large AMD (greater than 6%), allowing
high.target and the cross-reactive sequences are regulated differently, the
mixture of signals detected by the non-speciﬁc cross-reactive probes
will present signiﬁcant difﬁculties for the researcher with respect to
extrapolating representative biological information.
Oftentimes, the overall precision of microarray measurements is
determined by assaying technical replicates. The Illumina 27k
microarray has been demonstrated to possess a very high level of
precision, with an average correlation R2 of 0.992 between technical
replicates [4]. In this paper we assayed the precision of the microarray
by making use of the inadvertently replicated probes, that is, probes
with the same sequence(s) originally designed to target different but
highly homologous genes (Supplemental Table 2). We observed the
overall correlation coefﬁcient R2 betweenmeasurements of replicated
probes to be 0.991, which is very close to what was determined using
technical replicates (Fig. 2) [4]. Such a high level of precision enables
the microarray platform to be sensitive enough to robustly detect
small methylation differences (Table 4). In addition, the striking
similarity of the two correlation coefﬁcients (R2 of 0.992 and 0.991)
measured using technical replicates [4] and replicated probes
suggests that the small deviation from perfect correlation among
the technical replicates might be largely due to the slight imprecision
of the microarray.
In addition to the non-speciﬁc cross-reactive probes, we found a
small number of potentially signiﬁcant probes targeting polymorphic
SNP-containing CpG sites (Table 5).We demonstrated the variable but
sometimes drastic effect of SNPs on the observed methylation level ofs.
5% 6% 7% 8% 9% 10%
611 365 223 140 87 50
9% 5% 3% 2% 1% 1%
bes. The greater the AMD for repeat measurements of replicate probes, the lesser the
had large AMD, the greater the overall precision of the array platform. In this case, only
us to conclude that overall, the precision of most of the probes of the microarray is very
Table 5
Polymorphic CpGs targeted by the Illumina 27k array.
SNP at cytosine SNP at guanine
Probe_ID Target SNP_ID Alleles Probe_ID Target SNP_ID Alleles
cg00441136 KIF3B rs76661900 C/G cg00833777 ITGAM rs41439148 G/A
cg01784199 DNAJB4 rs41311176 C/T cg01756060 CDK6 rs36227868 G/A
cg06210526 CYP2F1 rs62117444 C/T cg26264314 NLRP5 rs62123572 G/A
cg09736922 THPO rs41266279 C/T cg26608667 C7orf50 rs62431996 G/A
cg10051054 CCDC27 rs41315312 C/T cg09196942 PRAMEF1 rs1852946 G/A
cg11717557 AP4B1 rs76985357 C/G cg12645742 SMAD6 rs62005619 G/A
cg16433922 SFRP4 rs62443106 C/A cg18133966 PLA2G1B rs41279094 G/A
cg17091851 CLEC18A rs62052566 C/T cg20530056 IKBKE rs41303980 G/A
cg19297688 INSL4 rs41313766 C/T cg21604615 SYTL1 rs41291086 G/A
cg21746459 MRPL50 rs41312232 C/T cg22745747 BMX rs41309563 G/A
cg24816298 PTH rs61882803 C/T cg24908058 CGB5 rs13345685 G/A
cg25839227 ABI3 rs61665126 C/G cg00620223 CENPF rs41277188 G/C
cg26330371 LMAN1 rs41487345 C/A cg01361777 DLG5 rs41274596 G/A
cg00729708 LASS3 rs55719509 C/A cg06723357 CUEDC1 rs62081764 G/A
cg01204439 TPK1 rs62498569 C/T cg07611925 KCNE2 rs41260744 G/A
cg12428604 TMEM60 rs41281016 C/A cg07973461 BAGE rs75358975 G/A
cg20484002 KRT28 rs71371447 C/T cg11249120 SAMD3 rs41285312 G/A
cg20676303 GAGE12I rs78333028 C/T cg15531099 LCE1D rs41268490 G/A
cg25463135 GBP7 rs61798772 C/T cg18568838 MRPS10 rs41273810 G/A
cg27360098 ELN rs41410045 C/T cg22228134 GZMH rs66505306 G/C
cg01962826 GRM4 rs41267667 C/T cg09220361 GABRG2 rs41303360 G/A
cg02246665 HCFC2 rs61937639 C/T cg09494188 SCGB1A1 rs41364547 G/A
cg05467918 ACADM rs61797339 C/A cg17524624 GSTK1 rs28969567 G/C
cg08587864 PIGC rs79638479 C/G cg20657383 CEACAM1 rs41415047 G/A
cg10222534 KCNJ14 rs41275770 C/T cg21414251 OR12D2 rs36210739 G/A
cg10995925 LTA rs36221311 C/G cg22022041 CCR9 rs41289608 G/A
cg15125424 SOCS2 rs61936494 C/T
cg17277529 FGF3 rs41408348 C/G
cg25372195 DCD rs61956600 C/T
cg03154500 CCDC127 rs62346523 C/A
cg03704393 ZNF169 rs62579660 C/T
cg03833774 ZCCHC5 rs41311547 C/T
cg05126264 IFNB1 rs41309794 C/T
cg05876094 CACYBP rs71645225 C/G
cg11075745 CLDN19 rs41269513 C/T
cg11465163 DIRAS3 rs41311160 C/T
cg12215675 TTLL2 rs41266329 C/T
cg16357921 CCRK rs41286033 C/A
cg21004129 IL8RA rs41509749 C/T
cg22518733 CCL3 rs41518648 C/T
cg25203856 NALP14 rs61063081 C/T
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Fig. 3. Effect of SNPs in polymorphic CpGs on the apparent methylation levels. The methylation levels of the SNP-residing CpGs shows variance likely to be according to SNP
genotypes for some of the probes. (A and B) Highly methylated CpGs showed 2 fold-change in their observed methylation levels possibly due to SNP heterozygosity among our
subjects. (C and D) CpGs with highly variable methylation levels that cannot be used to infer SNP type. Sample ID was generated from age and sex of samples, which consisted of
the same 12 males and 12 females from the sex-speciﬁc DNA methylation analysis.
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220 Y. Chen et al. / Genomics 97 (2011) 214–222CpGs (Fig. 3). The apparent methylation level measured by the
microarray may not represent the true methylation level of a
polymorphic CpG, because the reading of the microarray signal will
misinterpret a non-CpG SNP as an unmethylated CpG. As a result, any
associationmade between the methylation level of polymorphic CpGs
and the variable of interest could be false without consideration of the
SNP genotype of the subjects studied. One of the polymorphic CpGs
we identiﬁed (cg25839227), located ~1 kb downstream of the
transcription start site of ABI3, has been reported to negatively
regulate the metastatic capacity of tumor cells. This CpG site was also
found, using the Illumina 27k microarray, to carry differential
methylation signatures among different prognostic subsets of chronic
lymphocytic leukemia (CLL) [27]. However, the observed differences
in methylation could in fact be due to differences in SNP genotype
rather than differences in epigenetic regulation. Indeed, subjects with
different methylation levels of ABI3 belonging to the same CLL
prognostic group could be explained by differences in SNP genotype.
More recently, researchers have integrated genome-wide SNP data
with DNA methylation data to ﬁnd associations between SNPs and
CpG sites. Of interest, 4 of the polymorphic CpG sites we identiﬁed
were shown to be associated with other SNPs in cis [28]. This can be
explained by the close linkage of the cis-associated SNP and the
polymorphic CpG site within the same haplotype block. Thus, any
ﬁndings derived from these polymorphic CpGs should be interpreted
with care.
In summary, we report the existence of non-speciﬁc probes,
unreported replicated probes and probes targeting polymorphic CpGs
in the Illumina 27k microarray that might affect the interpretation of
data generated from this microarray. To our knowledge, this has not
been reported before. Users of this microarray platform should be
aware of the non-speciﬁc cross-reactive probes and other technical
issues presented in this paper in order to appropriately interpret
results generated by the use of this microarray. Our ﬁndings raise the
possibility of similar technical drawbacks in other microarray plat-
forms. Given the minimal number of problematic probes and the high
level of overall precision, the Illumina Inﬁnium HumanMethylation27
BeadChip provides an excellent microarray platform for DNA
methylation detection based on sodium bisulﬁte-modiﬁed DNA.
Notably, our data strongly support the use of independent validation
of microarray data using other methods for reliable interpretation of
epigenetic data.
4. Materials and methods
4.1. Sample preparation
Whole blood samples of 12 healthy males and 12 healthy females
(see x-axis of Supplemental Fig. 1 for subjects’ sex and age) were used
for sex-speciﬁc DNA methylation analysis. Genomic DNA were
extracted from lymphocytes and underwent bisulﬁte conversion
using the Qiagen EpiTect kit according to the manufacturer's protocol.
For microarray precision analysis, the 277 samples used were derived
from assorted tissues (saliva, placenta, whole blood, ﬁbroblast,
lymphoblastoid cell line) of healthy or diseased individuals. These
samples were prepared in the same way as those for sex-speciﬁc DNA
methylation analysis. All samples were obtained for other research
projects with informed consents obtained from all individuals.
4.2. Quality control
The Illumina Inﬁnium Human Methylation27 BeadChip was
processed as previously reported [29]. The microarray data were
analyzed using the BeadStudio (Methylation Module v3.2) software
provided by Illumina. For sex-speciﬁc DNA methylation analysis, all
samples had at least 27,390 CpGs with detection p value b0.05 (dp
b0.05). Detection p value provided by BeadStudio is a measure ofsignal quality. In addition, all samples had bisulﬁte conversion control
(BCC) value of at least 3704. BCC value provided by BeadStudio is a
measure of bisulﬁte conversion quality. All these samples were
considered to be high quality. For microarray precision analysis, the
samples were subjected to quality control of similar stringency. All
277 samples had minimal 98% CpG coverage (i.e., at least 27,000 CpGs
with dp b0.05) and BCC value of at least 4000.
4.3. Sex-speciﬁc DNA methylation analysis
In the BeadStudio software, an AVG_Beta value representing
methylation level was computed for each CpG site. Methylation
level is measured as the ratio of signal from a methylated probe
relative to the sum of signals from bothmethylated and unmethylated
probes. A Delta Beta value representing difference in methylation
level between males (n=12) and females (n=12) was also
computed for each CpG site. A non-parametric signiﬁcance test,
Mann–Whitney, was performed to ﬁnd CpGs with signiﬁcant
methylation difference. False discovery rate (FDR) correction for
multiple testing was applied. For the purpose of this study, we
considered only the methylation difference of FDR-adjusted p value
b0.05 to be signiﬁcant. The microarray data from this study have been
submitted to the NCBI Gene Expression Omnibus (http://www.ncbi.
nlm.nih.gov/geo) under accession nos. GSE23638.
4.4. Bisulﬁte-pyrosequencing
The bisulﬁte-converted DNA used for pyrosequencing was pre-
pared in the same way as for the Illumina microarray. The primers for
PCR ampliﬁcation and pyrosequencing were designed using the
PyroMark Assay Design v2.0 software (Qiagen). The forward and
reverse PCR primer for NUPL1 is 5′TTGAGTGGGGAGTTTAGAGAT′3 and
5′CGCCAGGGTTTTCCCAGTCACGACACTACTTCTATCTAACCTCCTACC′3,
which had a universal tag (ﬁrst 30-nt at the 5′ end) that annealed to
the universal biotinylated primer. The pyrosequencing primer is 5′
ATGTTTAGGAGGGATTTTT′3. Bisulﬁte-converted DNA (1 μl) was am-
pliﬁed using Hot-Start Taq-polymerase (Qiagen). Amplicons were
analyzed on the PyroMark Q24 pyrosequencer as speciﬁed by the
manufacturer (Qiagen), and % methylation was quantiﬁed as a ratio of
C (methylated C) to C+T (methylated C+unmethylated C) using
PyroMark Q24 software (Qiagen).
4.5. Identiﬁcation of non-speciﬁc probes
The 50-nucleotide probe target sequence was extracted from the
ALLELEA_PROBESEQ and ALLELEB_PROBESEQ columns in BeadStudio.
The ALLELEA_PROBESEQ targets the unmethylated DNA sequence, in
which all cytosines are converted to thymines; the ALLELEB_PROBE-
SEQ targets the methylated DNA sequence, in which the 5′cytosine of
CpGs are protected from the conversion. Therefore, in order to identify
cross-reactive sequences for both types of probe sequences, we need
to perform BLAT on both strands of unmethylated and methylated
genomes (total of 4 genomes). Because bisulﬁte conversion generated
2 non-complementary sequence strands, BLAT searches on one strand
did not equate to BLAT searches on the other strand. We downloaded
the genome from UCSC Genome Browser, Genome Assembly Mar.
2006 (NCBI36/hg18), the same reference genome used to design the
Illumina probes, and then we generated the reverse complement of
downloaded genome and performed 2 types of computational
bisulﬁte conversion (one assumed all CpGs were methylated and
the other assumed the opposite) on both genomes (the original and
the reverse complement) using simple Linux commands, such as sed,
rev, and tac. The BLAT was performed using the executables written
by Kent [30].
The output of 8 BLAT runs (2 types of probe sequences x 4 types of
genomes) were processed in 4 steps before further analyses. First, we
221Y. Chen et al. / Genomics 97 (2011) 214–222only kept sequence matches with negative strand sign (­), because we
only wanted the matches representing sequence hybridizing to the
probe sequence not the matches representing the actual probe
sequence itself. Second, duplicate results were removed based on
ProbeID and location of the sequence matches. Third, sequence
matches that had gaps and/or did not end with a match at nucleotide
position 50 were further removed in order to retain only the
sequences that ﬁt the criteria: gapless and end-nucleotide match in
the sequence alignment. Lastly, we only kept the sequence matches
that had at least 90% identity and at least 40–50matching bases in the
sequence alignment (“% identity” was calculated from dividing “the
number of matching bases” by “the span of the sequence match”). For
a probe to be considered as non-speciﬁc and potentially cross-
reactive, its BLAT result must have extra sequence match(es) beside
the perfect sequence match to its target sequence. The extra sequence
match(es)must also survive the above 4-step processing procedure in
order to identify sequence matches with a high likelihood of
representing true cross-reactivity. We chose 90% identity as a
threshold to justify the high sequence identity required for hybrid-
ization to occur [19]. The rationale of using a threshold of 40–50
matching bases was derived from the FLJ43276 probe (cg13150977),
which created an artifact of sex-speciﬁc methylation difference by
cross-reacting to two sequences on the Y chromosome each with only
41 matching bases. The end-nucleotide match was essential for cross-
reactivity to occur due to the nature of the microarray, in which the
detection signals were released only if the end nucleotide of the probe
was hybridized allowing single-base-extension to occur. Lastly, gaps
could compromise the hybridization between the probes and cross-
reactive sequences and therefore sequence matches should be
gapless.
4.6. Microarray precision analysis
The duplicate and triplicate probes were identiﬁed by ﬁnding
probes with the same 50-nucleotide probe sequences (Supplemental
Table 2). The correlation plot, reﬂecting the overall precision of the
microarray platform, was derived by plotting methylation level calls
of one of the same-target-sequence probes on X axis and another on Y
axis. The precision of repeat measurements was reﬂected by the
difference in methylation levels determined by the same-target-
sequence probes, or the absolute methylation difference (AMD)
within each set of duplicate and triplicate probes. AMDs were
calculated using AVG_Beta values derived from BeadStudio. Ques-
tionable calls of DNA methylation levels (measurement with
detection p value N0.05) were excluded for AMD calculation and
correlation plot.
4.7. Identiﬁcation of polymorphic CpGs
The chromosomal locations of the 27,578 CpGs interrogated by the
Illumina 27k microarray were extracted from the CHR and MAPINFO
columns in BeadStudio. By inputting chromosomal locations of CpGs,
SNPnexus (www.snp-nexus.org) can identify the polymorphic CpGs
with SNP at the cytosine position. By adding all CpG chromosomal
locations by 1, we can identify CpGs with SNP at the guanine position.
We thus have batch-queried 55,156 chromosomal locations for SNP.
The identiﬁed SNPs were further visually validated using UCSC
Genome Browser, Genome Assembly Mar. 2006 (NCBI36/hg18). The
validation serves two purposes: ﬁrst, to make sure the SNP actually
resides on a CpG site; second, to know exactly at where the SNP
resides, either guanine or cytosine.
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